Ionis director sells shares after option exercise
Ionis Pharmaceuticals director Allene M. Diaz exercised stock options and then sold the resulting shares.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Ionis Pharmaceuticals director Allene M. Diaz exercised stock options and then sold the resulting shares. On July 7, 2026, Diaz exercised a non-qualified stock option to acquire 10,111 shares of common stock at $47.11 per share, then sold 10,111 shares in open-market transactions at a weighted average price of $85.4156 per share under a pre-arranged Rule 10b5-1 trading plan. After these transactions, Diaz directly owned 3,811 shares of Ionis common stock.
Insider Trade Summary 10b5-1
Exercise and Sale: 10,111 shares ($387K approx. pre-tax spread)
Exercise and Sale
3 txns
Insider
Diaz Allene M.
Role
Director
Sold
10,111 shs ($864K)
Approx. gross sale proceeds
$864K
Approx. exercise cost
$476K
Approx. pre-tax spread
$387K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Non-Qualified Stock Option (right to buy) | 10,111 | $0.00 | $0.00 |
| Exercise | Common Stock | 10,111 | $47.11 | $476K |
| Sale | Common Stock | 10,111 | $85.4156 | $864K |
Holdings After Transaction:
Non-Qualified Stock Option (right to buy) — 0 contracts (Direct);
Common Stock — 3,811 shares (Direct)
Footnotes (2)
- F1. Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on November 25, 2025.
- F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $85.040 to $85.730 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.
Key Figures
Shares sold: 10,111 shares
Sale price range: $85.040–$85.730 per share
Options exercised: 10,111 shares
+3 more
6 metrics
Shares sold
10,111 shares
Common Stock open-market sale on July 7, 2026 at weighted average $85.4156
Sale price range
$85.040–$85.730 per share
Price range for multiple sale transactions on July 7, 2026
Options exercised
10,111 shares
Non-Qualified Stock Option exercised into common stock on July 7, 2026
Option exercise price
$47.11 per share
Exercise price of Non-Qualified Stock Option
Shares held after transaction
3,811 shares
Common Stock directly owned by Diaz after the reported trades
Rule 10b5-1 plan adoption date
November 25, 2025
Date Diaz adopted the trading plan used for these sales
Key Terms
Rule 10b5-1 Trading Plan, Non-Qualified Stock Option, weighted average price
3 terms
Rule 10b5-1 Trading Plan regulatory
"Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on November 25, 2025."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
Non-Qualified Stock Option financial
"Non-Qualified Stock Option (right to buy) with an exercise price of $47.1100 per share."
A non-qualified stock option (NSO) is a contract that lets an employee or service provider buy company shares at a fixed price for a set period, like a voucher to purchase stock later at today’s price. It matters to investors because exercising NSOs creates ordinary income for the holder and can increase share count, affecting a company’s earnings and ownership mix; think of it as a future sale that can dilute existing shareholders and has immediate tax consequences for the recipient.
weighted average price financial
"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $85.040 to $85.730 inclusive."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Ionis (IONS) director Allene M. Diaz report in this Form 4?
Allene M. Diaz reported exercising a stock option for 10,111 Ionis shares and then selling 10,111 shares in the open market. These trades were executed under a pre-arranged Rule 10b5-1 trading plan on July 7, 2026.
What stock options did the Ionis (IONS) director exercise in this filing?
Diaz exercised a non-qualified stock option covering 10,111 shares of Ionis common stock at an exercise price of $47.11 per share. Following the exercise, the option position reported in this filing was fully used, with zero derivative shares remaining.
What is the price range of Ionis (IONS) trades disclosed in this Form 4?
The filing reports that the 10,111 shares were sold in multiple transactions at prices ranging from $85.040 to $85.730 per share. The reported $85.4156 figure is a weighted average across these individual trades.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates